	News Releases

	Fact Sheet

	Photos

	Press Kits

	Media Contact Info

Fact Sheet

•	World Headquarters: 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530

•	Chairman and CEO: Fred Hassan

•	Number of Employees: about 55,000

•	Net Sales (2007): $12.7 billion

•	Business operations in more than 140 countries

•	Largest-selling products: VYTORIN, ZETIA, REMICADE, NASONEX

•	R&D investment (2007): $2.9 billion

•	Web Site Address: www.schering-plough.com

•	Stock Exchange Listings: New York Stock Exchange (SGP)

•	Unlisted Trading: Boston Stock Exchange Cincinnati Stock Exchange Midwest Stock Exchange Pacific Stock Exchange Philadelphia Stock Exchange

•	Key Products: ASMANEX (mometasone furoate) AVELOX (moxifloxacin) CAELYX (pegylated liposomal doxorubicin HCI) [marketed internationally only] CLARINEX (desloratadine) CLARITIN (loratadine) FOLLISTIM (follitropin beta) INTEGRILIN (eptifibatide) INTRON A (interferon alfa-2b) NASONEX (mometasone furoate monohydrate) NOXAFIL (posaconazole) PEGINTRON (peginterferon alfa-2b) REMICADE (infliximab) [marketed internationally only] TEMODAR (temozolomide) VYTORIN (ezetemibe/simvastatin) (Joint venture with Merck & Co., Inc.) ZEMURON (rocuronium bromide) ZETIA (ezetimibe) (Joint venture with Merck & Co., Inc.)

•	Areas of research: cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health *VYTORIN and ZETIA are managed through a joint venture with Merck & Co.,Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.



	Brochure on the Combination



	CEO Fred Hassan's Remarks from the 3rd Annual Cardiovascular Summit: "Improving Cardiovascular Care: A Noble Mission." Read More >



	© 2003-2008 Schering-Plough Corporation. Please see our legal notice, privacy policy and forward-looking statement.